Next Article in Journal
Hypermetabolism and Substrate Utilization Rates in Pheochromocytoma and Functional Paraganglioma
Next Article in Special Issue
Postnatal Conditional Deletion of Bcl11b in Striatal Projection Neurons Mimics the Transcriptional Signature of Huntington’s Disease
Previous Article in Journal
Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer
Previous Article in Special Issue
CAG Repeat Instability in the Peripheral and Central Nervous System of Transgenic Huntington’s Disease Monkeys
 
 
Review

Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington’s Disease

Department of Neuroscience, School of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Esther Pérez-Navarro and Jordi Creus-Muncunill
Biomedicines 2022, 10(8), 1979; https://doi.org/10.3390/biomedicines10081979
Received: 30 June 2022 / Revised: 10 August 2022 / Accepted: 12 August 2022 / Published: 15 August 2022
Huntington’s Disease (HD) is a devastating neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene, for which no disease modifying therapies are currently available. Much of the recent research has focused on developing therapies to directly lower HTT expression, and while promising, these therapies have presented several challenges regarding administration and efficacy. Another promising therapeutic approach is the modulation of HTT post-translational modifications (PTMs) that are dysregulated in disease and have shown to play a key role in HTT toxicity. Among all PTMs, modulation of HTT phosphorylation has been proposed as an attractive therapeutic option due to the possibility of orally administering specific kinase effectors. One of the kinases described to participate in HTT phosphorylation is Protein Kinase CK2. CK2 has recently emerged as a target for the treatment of several neurological and psychiatric disorders, although its role in HD remains controversial. While pharmacological studies in vitro inhibiting CK2 resulted in reduced HTT phosphorylation and increased toxicity, genetic approaches in mouse models of HD have provided beneficial effects. In this review we discuss potential therapeutic approaches related to the manipulation of HTT-PTMs with special emphasis on the role of CK2 as a therapeutic target in HD. View Full-Text
Keywords: post-translation modifications; CK2; Huntington’s disease; kinase inhibition; HTT phosphorylation post-translation modifications; CK2; Huntington’s disease; kinase inhibition; HTT phosphorylation
Show Figures

Figure 1

MDPI and ACS Style

White, A.; McGlone, A.; Gomez-Pastor, R. Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington’s Disease. Biomedicines 2022, 10, 1979. https://doi.org/10.3390/biomedicines10081979

AMA Style

White A, McGlone A, Gomez-Pastor R. Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington’s Disease. Biomedicines. 2022; 10(8):1979. https://doi.org/10.3390/biomedicines10081979

Chicago/Turabian Style

White, Angel, Anna McGlone, and Rocio Gomez-Pastor. 2022. "Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington’s Disease" Biomedicines 10, no. 8: 1979. https://doi.org/10.3390/biomedicines10081979

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop